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RESUMO – Os doentes com transplante de órgão-sólido têm maior incidência de carcinoma espinocelular (CEC) do que a popu-
lação em geral. Esta maior incidência deve-se a diversos fatores, entre os quais, exposição crónica à radiação ultravioleta, infeção 
por papiloma vírus humano, fármacos imunossupressores, entre outros. A prevenção primária é crucial, porque além dos CEC 
serem mais frequentes nos doentes transplantados, são também mais agressivos e têm, portanto, um prognóstico pior. Os novos 
fármacos imunossupressores estão associados com um risco menor de desenvolvimento de CEC, no entanto, podem ter mais 
efeitos adversos, levando ao abandono da terapêutica. Em relação às opções terapêuticas para CEC, estas variam entre cirurgia, 
radioterapia e terapêutica sistémica, apesar de existirem poucos estudos em doentes com transplante de órgão-sólidos, em relação 
à imunoterapia e inibidores do recetor do fator de crescimento epidérmico.
PALAVRAS-CHAVE – Carcinoma de Células Escamosas; Imunossupressão/efeitos adversos; Neoplasias da Pele; Trans-
plantados.
Cutaneous Squamous Cell Carcinoma in Solid Organ 
Transplant Patients 
ABSTRACT – Solid organ transplant recipients (SOTR) are more likely to develop cutaneous squamous cell carcinoma (CSCC), com-
pared to the general population. This increased incidence is due to several factors including chronic ultraviolet radiation exposure, 
human papillomavirus (HPV) infection, immunosuppressive medication, among others. Primary prevention is crucial, because not 
only are cutaneous squamous cell carcinomas more frequent in SOTR, but they are also more aggressive and have therefore a worse 
prognosis. Newer immunosuppressive drugs are associated with a smaller risk of developing CSCC, but they can have more adverse 
events, prompting patients to abandon therapy. Concerning treatment options for CSCC, they range from surgery, radiotherapy, and 
systemic therapy, although there are few studies in SOTR concerning the use of immunotherapy and epidermal growth factor receptor 
(EGFR) inhibitors.  
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INTRODUCTION
After basal cell carcinoma (BCC), the second most com-
mon malignancy is cutaneous squamous cell carcinoma 
(CSCC).1,2 Its incidence has continued to rise,  with estima-
tes that it has increased from 50% to 300% in the last thirty 
years, and that in the next decade, its incidence is predicted 
to double.3-5
For Caucasians, the risk of developing a CSCC in a 
lifetime is 7% to 11%.6 The risk is much higher if we take 
into account, solid organ transplant recipients (SOTR), who 
have a 65-250-fold greater risk.7,8 In contrast, the incidence 
of basal cell carcinoma is only 6-10 fold higher in SOTR.9,10
Consequently, instead of the normal BCC/CSCC ratio of 
4:1 in the general population, this ratio has been reported 




In comparison with renal or liver transplant recipients, 
heart or lung transplant recipients have been found to have 
an even higher incidence of CSCC.10 This incidence is pro-
bably due to more intensive immunosuppressive regimens 
required after heart or lung transplants as well as the older 
age of transplanted patients.9
For localized CSCC, the ten-year-survival after surgery 
surpasses 90%, but these tumors can be locally invasive or 
even metastatic, with rates of lymph node metastases of 
about 4% and mortality rates of almost 2%.11,12 In SOTR, 
not only are CSCC more frequent, but they are also more 
aggressive, with greater tumor depth, higher rates of re-
currence and higher rates of local and distant invasion.13,14
PORTUGUESE REALITY 
In the last 10 years, four reviews about cutaneous ma-
lignancies in SOTR were published.15-18 Data about these 
studies is summarized in Table 1. In these publications, the 
number of transplant recipients ranged from 127-319 pa-
tients, with a mean age of 50.7-63.5 years and a predo-
minance of male patients (60.9%-88.9%). The number of 
patients who developed CSCC fluctuated between 10-62, 
with an average time elapsed since transplant of 5-8 years.
Contrary to the inverted ratio 4:1 of BCC and CSCC 
described in several anglo-saxonic publications,8 in the 
Portuguese series this inversion has not been verified.15-18 
Instead, ratios of 1:1 have been found between BCC and 
CSCC. This is similar to other Southern European reports, 
such as those from Spain19,20 and Italy.21 These ratios are 
attributed to genetic differences as well as sun exposure 
habits.16,18
RISK FACTORS
The risk of developing a CSCC at 10 years post-trans-
plant is estimated to be 10%-27% and at 20 years post-
-transplant is 40%-60%.9
The most contributing factor is ultraviolet (UV) radiation, 
explaining why the majority of CSCC occur in sun-exposed 
locations (Fig.s 1 and 2).22 Additional contributing factors are 
advanced age, male gender, skin phototype I or II, infection 
with beta human papillomaviruses (HPV), genetic factors and 
the immunosuppressive medication that is needed to main-
tain the transplanted organ.16,17,23
UV radiation exposure causes mutations in tumor sup-
pressor genes, such as TP53 and NOTCH, and oncogenes, 
like HRAS, NRAS and KRAS.24 Even sun-exposed skin, without 
clinical abnormalities, has a similar amount of mutations 
when compared with oropharyngeal squamous cell carcino-
mas, although it has a 10-fold lower mutations amount than 
that reported for CSCC.24
HPV have also been implicated in the pathogenesis of 
CSCC (Fig. 3).25,26 It is well established the role of alpha-
-genus HPV, such as HPV 16 and HPV 18, in the develop-
ment of anogenital carcinoma, and they are also involved 
in the formation of head and neck CSCC and periungual 
CSCC.27 
Beta-genus HPV, like HPV5, HPV8 and HPV9 can be pre-
sent in the skin of healthy people, but their levels rise with 
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Figure 1 - Cutaneous squamous cell carcinoma on the hand of a 
renal transplant recipient.  































2010-2011 127 renal 53 67% 10 96 1:1
Pinho 
et al17
2004-2013 288 renal 61.9 66% 62 64 1:1
Garrido 
et al18
2008-2014 197 renal 50.7 60.9% 15 Not specified 1.1:1
+ Mean age is expressed in years *Time interval between transplant and CSCC appearance is in months.
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immunosuppression.28,29 Their presence has been found in 
almost 90% of CSCC in SOTR and has been associated 
with twice the risk of CSCC in SOTR.28,29
A supporting finding for the implication of HPV in CSCC 
is that actinic keratosis, which are precursors of CSCC, 
also have an elevated number of Beta-HPV copies.30 
The mechanism of action that is hypothesized in the 
genesis of anogenital CSCC involves the inhibition of TP53 
and retinoblastoma protein by the HPV’s oncoproteins E6 
and E7.31 Beta-HPV may allow the accumulation of UVR in-
duced mutations, through several mechanisms, for instan-
ce, degradation of Bak (involved in cellular apoptosis) and 
inhibition of Notch tumor suppression.24,27,28
Regardless of these findings, there are some studies in 
which HPV is found in low or absent activity in CSCC, and 
this led to the “hit-and-run” hypothesis, that states that Be-
ta-HPV are involved in the formation of the tumor but they 
are not necessary for its maintenance, contrary to alfa-HPV 
in anogenital SCC.27,28,31
Another important risk factor is the immunosuppressive 
medication used for the organ maintenance.32 Sirolimus 
has been demonstrated to reduce the number of CSCC in 
comparison to calcineurin inhibitors tacrolimus and cyclos-
porine.33 The benefit of switching to sirolimus is supposed 
to be greatest after the development of one CSCC and ne-
gligible when there are multiple prior CSCC. Therefore, it 
has been suggested to switch from calcineurin inhibitors to 
sirolimus after the first post-transplant CSCC.3,8,13 Despite 
this, sirolimus has more serious adverse events per patient, 
prompting more patients to discontinue treatment, and in a 
meta-analysis it has been associated with an increased risk 
of death, although this remains controversial.33,34 
Azathioprine, that acts as a photosensitizer to UVA, is 
also responsible for an increased risk of CSCC.16 Myco-
phenolate mofetil seems to be associated with lesser risk 
and should be considered as an alternative option to aza-
thioprine.35
All the factors cited above, act synergistically and as 
a result of an interaction there can be development and 
progression of CSCC in solid organ transplant recipients.24
PREVENTION
Since SOTR have a higher incidence of CSCC and these 
are more aggressive, with an increased risk of metastasis 
of 5%-7%, skin cancer prevention is essential.36
Given that the most important risk factor is UV radia-
tion, emphasis on sunscreen use and sun protection must 
be made.9
Before transplant, patients should have a full-body skin 
examination, with a subsequent periodic assessment de-
pending on previous or concomitant skin premalignant 
and malignant lesions.9 (Table 2). An annual screening is 
suggested for patients without pre-malignant or malignant 
lesions. Patients with actinic keratosis or one prior nonme-
lanoma skin cancer should be evaluated at 3-6 months 
and if a high-risk CSCC is found the follow-up should be 
every 3 months. In patients presenting with a metastatic 
squamous cell carcinoma, an examination after 1-3 mon-
ths is advised.9
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Figure 2 - Recurrence of cutaneous squamous cell carcinoma on the 
head of a renal transplant recipient. Squamous cell carcinoma is more 
frequent in sun-exposed locations.  
Figure 3 - Cutaneous squamous cell carcinoma on the genital area 
of a male patient. HPV infection is a contributing factor in the develop-
ment of CSCC, especially on this area.  
Table 2 - Recommended screening interval, 
according to patient’s risk factors.
Risk factors Periodic assessment
Absence of pre-malignant /
malignant lesions
Annual screening
Pre-malignant lesions/ One prior 
nonmelanoma skin cancer
3-6 months
Multiple prior nonmelanoma skin 
cancers/ High-risk CSCC
3 months




There are three main staging systems used for staging 
CSCC: the American Joint Committee on Cancer (AJCC), 
the Union for International Cancer Control (UICC) and, 
more recently, the Brigham and Women’s Hospital Tumor 
staging system.13.22 These staging systems have into account 
factors such as: tumor dimensions, perineural invasion, 
depth of invasion and poorly differentiated histology.13.22
Nevertheless, some criteria with prognostic influence, 
like tumor location and immunosuppression are not consi-
dered in any of the main staging systems, causing a poten-
tial underestimation of CSCC prognosis in SOTR.37
TREATMENT
Considering the aggressiveness of CSCC in SOTR, treat-
ment of pre-malignant lesions should be sought out and if 
there is suspicion of transformation into malignant lesions, 
biopsy or excision should be performed.38
In terms of topical therapies for the treatment of actinic 
keratosis, there is a wide range of options available: diclo-
fenac, 5-fluorouracil, imiquimod, laser, cryotherapy, among 
others.22,38 
In single lesions, local destructive options, such as cryo-
therapy or electrocautery and curettage can be considered. 
Clearance of 41% of lesions has been achieved with topical 
diclofenac and 62% clearance has been obtained with topi-
cal imiquimod.39,40 Imiquimod is an immunomodulatory agent 
that has anti-viral and anti-tumor properties.41 It has been ad-
vised to limit its use to an area of 60-100 cm2, because albeit 
rare, imiquimod has been linked to induction of systemic im-
munostimulation.42 However some studies have demonstra-
ted that the actual systemic absorption of topical imiquimod is 
minimal and hundreds of patients have been treated without 
graft rejection.42 For areas with extensive lesions, photodyna-
mic therapy should be considered, and has been proven to be 
more effective than imiquimod.38,43 
For CSCC, surgery is the gold standard treatment, not only 
because it allows tumor removal but also histologic verifica-
tion.44 The recommended surgical margins depend on the size 
of the tumor, with margins of 0.4 cm being advocated for 
tumors inferior to 2 cm, and margins of 0.6 cm for tumors 
larger than 2 cm.45
For high risk locations (scalp, ears, eyelids, nose), Mohs 
micrographic surgery is recommended, but if this is not pos-
sible and standard excision is performed, avoidance of sig-
nificant tissue rearrangement is necessary, before confirming 
histologic margins are free of tumor.44-46 
Although radiotherapy for CSCC has declined, it can be 
a viable alternative when surgical options are not possible, 
particularly for primary tumors.44 An overall control rate was 
achieved for 89% of previously untreated CSCC and 68% for 
recurrent CSCC.47 Radiotherapy is also used as an adjuvant 
treatment of surgery, for CSCC with perineural invasion, al-
though it has not been established that it improves survival.48,49
In locally advanced or metastatic CSCC, if surgery or ra-
diotherapy are not feasible, systemic therapy with cytotoxic 
agents (platinum, interferon-alpha, 5-fluouracil and taxanes), 
epidermal growth factor receptor (EGFR) inhibitors and im-
munotherapy can be used.22 However, in SOTR there are few 
studies evaluating the safety and efficacy of these treatments.22 
Depending on the treatment combination used, respon-
se rates with chemotherapy have ranged from 14% to 86%, 
with cisplatin and 5-fluouracil obtaining the best results.50 
Complete remission was achieved in 43% of patients trea-
ted in one series, however side effects of these treatments 
should be considered.50
The EGFR inhibitors, cetuximab and panitumumab have 
shown some response against advanced CSCC, with res-
ponse rates of 27%, and 31%, respectively, evaluated in im-
munocompetent individuals.49-52 These can represent valid 
options for tumors expressing high levels of EGFR, however 
in SOTR there are few studies available.50,51
Immunotherapy with anti-PD-1 monoclonal antibo-
dy, specifically cemiplimab, was approved in 2018 for the 
treatment of advanced CSCC.53 The response rate was 47% 
with an overall survival of 81%.53 Despite these high res-
ponse rates, in SOTR, there is a risk of organ rejection with 
checkpoint inhibitors, that is almost 50% within a month of 
therapy.22
CHEMOPROPHYLAXIS
For patients who develop more than 5 CSCC/per year, 
systemic retinoid therapy should be considered.54 Acitretin, 
a systemic retinoid, has reduced the incidence of actinic ke-
ratosis and CSCC in SOTR.55 Starting with a low dose of 10 
mg/daily is recommended, with maximum doses of 30 mg/
daily, in order to prevent patient loss of compliance, due to 
adverse events.56
However, there are several contraindications for their 
use, like pregnancy, severe hyperlipidemia, and a rebound 
effect when therapy is discontinued.57
For this reason, therapy with systemic retinoids should be 
carefully weighted, as patients can experience a high num-
ber of CSCC in a short period of time.55,56
Another option that has been studied for chemopro-
phylaxis, is oral capecitabine, a pro-drug of 5-fluorouracil, 
that has also shown to reduce the incidence of pre-malig-
nant and malignant lesions after solid organ transplant, 
with less side effects than systemic retinoids.58 
CONCLUSION
Cutaneous squamous cell carcinoma incidence has been 
rising and is predicted to continue to increase. These tu-
mors are even more common and aggressive in solid organ 
transplant recipient patients. Ultraviolet radiation is the most 
important risk factor for the development of CSCC and so 
primary prevention must be implemented amongst patients.
Immunosuppressive medication is necessary to prevent 
organ rejection but is also associated with an increased risk 
of developing skin malignancies. Particularly, old immuno-
suppressive drugs, such as, azathioprine, cyclosporine and 
tacrolimus have been linked to a higher incidence of CSCC. 
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Primary treatment option is surgical excision with surgi-
cal margins depending on tumor’s size. Radiotherapy can 
also be used as a therapeutic alternative. Chemoprophyla-
xis with acitretin should be considered for patients that de-
velop more than 5 CSCC/per year.
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